Randomized phase 2 study of GMI-1070 in SCD: Reduction in time to resolution of vaso-occlusive events and decreased opioid use

Blood

Volumn 125, Issue 17, 2015, Pages 2656-2664

  Telen, Marilyn J ^a   Wun, Ted ^b   McCavit, Timothy L ^c   De Castro, Laura M ^d   Krishnamurti, Lakshmanan ^e   Lanzkron, Sophie ^f   Hsu, Lewis L ^g   Smith, Wally R ^h   Rhee, Seungshin ⁱ   Magnani, John L ^j   Thackray, Helen ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

ⁱ RHO INC   (United States)

^j GlycoMimetics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE; PLACEBO; RIVIPANSEL; ANALGESIC AGENT; GLYCOLIPID; GMI-1070; NARCOTIC ANALGESIC AGENT;

ACUTE CHEST SYNDROME; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADOLESCENT; ADULT; ANALGESIA; ARTICLE; BLOOD VESSEL OCCLUSION; CHILD; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL TOXICITY; HEPATOBILIARY DISEASE; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE; KIDNEY DISEASE; LENGTH OF STAY; LEUKOCYTOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL CRISIS; TREATMENT OUTCOME; URINARY EXCRETION; URINARY TRACT DISEASE; VASOOCCLUSIVE CRISIS; VIRUS INFECTION; ANEMIA, SICKLE CELL; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; VASCULAR DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; CHILD; DOUBLE-BLIND METHOD; FEMALE; GLYCOLIPIDS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VASCULAR DISEASES; YOUNG ADULT;

EID: 84928492198     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-583351     Document Type: Article

References (32)

1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010; 38(suppl 4):S512-S521.
2. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-4336.
3. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013; 381(9861):142-151.
4. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323-327.
5. Lanzkron S, Haywood C Jr, Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol. 2006; 81(12):927-932.
6. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13): 1645-1651.
7. Brittain JE, Han J, Ataga KI, Orringer EP, Parise LV. Mechanism of CD47-induced alpha4beta1 integrin activation and adhesion in sickle reticulocytes. J Biol Chem. 2004;279(41): 42393-42402.
8. Brittain JE, Mlinar KJ, Anderson CS, Orringer EP, Parise LV. Integrin-associated protein is an adhesion receptor on sickle red blood cells for immobilized thrombospondin. Blood. 2001;97(7):2159-2164.
9. 2+ entry pathway involved in deoxygenation-induced phosphatidylserine exposure in red blood cells from patients with sickle cell disease. Pflugers Arch. 2013;465(11): 1651-1660.
10. Hines PC, Zen Q, Burney SN, et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood. 2003;101(8): 3281-3287.
11. Trinh-Trang-Tan MM, Vilela-Lamego C, Picot J, Wautier MP, Cartron JP. Intercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium. Haematologica. 2010;95(5):730-737.
12. Udani M, Zen Q, Cottman M, et al. Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin. J Clin Invest. 1998;101(11):2550-2558.
13. Zennadi R, Moeller BJ, Whalen EJ, et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood. 2007;110(7):2708-2717.
14. Zennadi R, Whalen EJ, Soderblom EJ, et al. Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood. 2012;119(5): 1217-1227.
15. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol. 2002;9(2):101-106.
16. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA. 2002; 99(5):3047-3051.
17. Zennadi R, Chien A, Xu K, Batchvarova M, Telen MJ. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood. 2008;112(8):3474-3483.
18. Chang J, Patton JT, Sarkar A, Ernst B, Magnani JL, Frenette PS. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 2010;116(10):1779-1786.
19. Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J. 2001;18(3):205-207.
20. Lopez BL, Flenders P, Davis-Moon L, Corbin T, Ballas SK. Clinically significant differences in the visual analog pain scale in acute vasoocclusive sickle cell crisis. Hemoglobin. 2007;31(4):427-432.
21. Styles L, Wun T, De Castro LMD, et al. GMI-1070, a pan-selectin inhibitor: safety and PK in a phase 1/2 study in adults with sickle cell disease [abstract]. Blood. 2010;116(21). Abstract 1632.
22. Gladwin MT, Kato GJ, Weiner D, et al; DeNOVO Investigators. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011;305(9): 893-902.
23. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 2001; 286(17):2099-2106.
24. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007;98(2): 392-396.
25. Styles L, Wager CG, Labotka RJ, et al Sickle Cell Disease Clinical Research Network (SCDCRN). Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br J Haematol. 2012;157(5): 627-636.
26. Vichinsky EP, Neumayr LD, Earles AN, et al National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-1865.
27. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79(1):17-25.
28. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288-1294.
29. Frei-Jones MJ, Field JJ, DeBaun MR. Multimodal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate. Pediatr Blood Cancer. 2009;53(3): 401-405.
30. Frei-Jones MJ, Field JJ, DeBaun MR. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatr Blood Cancer. 2009;52(4): 481-485.
31. Wun T, Styles L, DeCastro L, et al. Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS ONE. 2014;9(7): e101301.
32. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013;122(24):3892-3898.